A comparison of the efficacy and effectiveness of dihydroartemisinin-piperaquine and artesunate-mefloquine in the treatment of falciparum malaria
Completed
- Conditions
- Falciparum malariaInfections and Infestations
- Registration Number
- ISRCTN27914471
- Lead Sponsor
- Doctors Without Borders (Medecins sans Frontieres [MSF]) (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 640
Inclusion Criteria
1. Patients with fever (axillary temperature >37.5°C), or a history of fever within 48 hours
2. Confirmed falciparum malaria (mixed infection P. falciparum with P. vivax and/or P. malariae were included), with more than 500 but less than 100,000 asexual parasites per ml
Exclusion Criteria
1. Signs of severe and complicated malaria
2. Children below one-year-old
3. Pregnant women
4. Patients with a history of taking mefloquine during the previous two months
5. Patients taken any other antimalarial drugs in the previous 48 hours
6. Patients with a history of psychiatric diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Polymerase chain reaction (PCR) adjusted parasitological failure rates by day 42
- Secondary Outcome Measures
Name Time Method 1. Vivax appearances<br>2. Gametocytaemia (person gametocyte weeks between day 0 and 42)<br>3. Whole blood piperaquine levels at day 7<br>4. Adverse effects